TheraCryf Plc

LSE • Healthcare • Biotechnology • Quote as of 10/27/2026 16:13

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeLSE

Market Capitalization3.8 mln

Float1,515 mln

Earnings Date12/09/2026

Piotroski F-Score

1 / 9

Very weak

1-Year Forecast

1.19

Transformational upside

Relative Strength

47 / 100

In line with market

Debt / Equity

0.00

Debt-free

ROE

-78.54

Deeply negative

ROA

-55.57

Deeply negative

Business Description

Theracryf Plc is a UK-based drug development company focused on treating cancer and brain-related conditions. Its pipeline includes compounds targeting binge eating disorder, anxiety, fatigue, narcolepsy, and glioblastoma, a severe form of brain cancer. Founded in 2014 and headquartered in Nether Alderley, the company was previously known as Evgen Pharma plc before rebranding in April 2024.

Key Fundamentals

EPS-0.20

ROE-78.54

ROIC-100

ROA-55.57

EBITDA, mln-3.55

EV / EBITDA-0.88

EV / EBIT-0.87

Quote Details

Last 0.1765

Change -0.0005 (-0.28%)

Open 0.1765

Volume 566,572

Turnover 100,000

Average Volume 5,634,486

Financial Ratios

Leverage Ratio1.77

Current Ratio1.36

Price / Book1.75

Debt / Equity0.00

Financial Strength

Piotroski F-Score 1 / 9

1-Year Target Price1.19

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	-3.23%	13 / 100
1 Month	-1.94%	37 / 100
2 Months	-19.77%	7 / 100
6 Months	-19.77%	11 / 100
1 Year	-11.84%	17 / 100